Trial
NCT03310320
Study to Determine if AZD0284 is Effective and Safe in Treating Plaque Psoriasis
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
AstraZeneca
Collaborators
—
Condition
Plaque Psoriasis Vulgaris
Intervention
AZD0284 oral solution 2.5 mg/mL
Why stopped
The study is temporarily suspended due to preclinical findings that are currently under evaluation
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-04-25